Skip to main content
Advertisement
Live broadcast

Scientists talked about the early atrophy of two brain regions in Alzheimer's disease

Bioengineer Miller: atrophy is possible 10 years before the symptoms of Alzheimer's disease
0
Photo: IZVESTIA/Vasilisa Pushkareva
Озвучить текст
Select important
On
Off

Scientists from Johns Hopkins University in the United States have found that in the early stages of Alzheimer's disease, two areas of the brain associated with memory and emotions can lose volume faster than the hippocampus. In the images, atrophy was more pronounced where tau protein, one of the markers of the disease, accumulated. What changes are visible in the images and whether it is possible to assess the risk of illness based on them — in the Izvestia material.

Which parts of the brain lose volume earlier than the hippocampus

The hippocampus is involved in the formation of new memories. His condition has long been studied as one of the signs of Alzheimer's disease. The Johns Hopkins University team took a closer look at the two structures next to it. The entorhinal cortex connects the hippocampus to other areas of the cortex and helps extract memories of events. The amygdala, or amygdala, is involved in processing emotions and influences how experiences are remembered.

The researchers analyzed the MRI scans of 1,149 people from two independent projects, ADNI and BIOCARD. The samples included people with preserved cognitive functions, patients with moderate cognitive impairment and dementia. Each participant had at least three MRIs. By comparing the images taken in different years, the scientists calculated the rate at which the volume of each area of the brain changed.

In both samples, the entorhinal region and the amygdala lost volume faster than the hippocampus. Thus, in the ADNI project, the volume of the hippocampus decreased by an average of 1.65% per year in people with moderate cognitive impairment. For the amygdala, this indicator was 3.26%, and for the entorhinal region, which was measured together with the adjacent transenthinal cortex, it was 3.53%.

In the entorhinal region, volume loss was associated with cortical thinning. The amygdala changed unevenly. The atrophy affected several of his internal organs the most. When measuring the entire structure, these local changes may be less noticeable.

Where did the ten-year estimate come from

The ten-year estimate was also found in earlier work with Miller's participation. In 2014, scientists analyzed the data of the participants of the BIOCARD project, whose cognitive functions were preserved at the time of inclusion in the study. According to the authors' calculations, the acceleration of atrophy of the entorhinal cortex could begin eight to ten years before the symptoms. For the amygdala, the estimated time was about three years.

"We found that signs of brain atrophy can be noticeable as early as ten years before the onset of clinical symptoms," said Michael Miller, head of the Department of Biomedical Engineering at Johns Hopkins University.

Alzheimer's disease accounts for 60 to 70% of dementia cases worldwide, according to WHO estimates. Scientists are looking for signs by which it would be possible to determine who has an increased risk of memory and thinking impairment. This would help to select participants for trials of therapy, which would be started even before the onset of symptoms.

How tau protein is related to brain atrophy

MRI allowed us to measure how the size and shape of brain areas change. To find out what is happening in the same areas at the protein level, the scientists used positron emission tomography (PET). The images obtained by the two methods were combined and the rate of atrophy was compared with the amount of accumulated tau protein.

Normally, tau protein helps to maintain the microtubules through which substances move inside the nerve cell. In Alzheimer's disease, altered tau molecules stick together and form clusters inside neurons — neurofibrillary tangles. Another characteristic feature of the disease is plaques of beta—amyloid that form between cells.

The stronger the tau protein signal on the PET, the faster the corresponding areas of the brain lost volume. For the amygdala, the authors separately compared the MRI data with a map of the distribution of protein clusters compiled during the postmortem examination of a brain tissue sample in an earlier work. In the external amygdala, where the tangle density was lower, atrophy was also less pronounced.

The researchers want to study in more detail what happens to cells in the areas where tau protein accumulates and how these changes are related to tissue loss. According to Miller, such work may suggest which processes should be influenced when developing a therapy.

Is it possible to predict memory impairment using MRI

The authors tested how well MRI measurements distinguish between people with preserved cognitive functions and participants with early moderate impairments. The analysis included 346 people from the first group and 210 from the second. With moderate cognitive impairment, it may be more difficult for a person to remember new information, while they usually remain independent in their daily activities.

Based on measurements of the hippocampus, the model received 0.635 on a scale where 0.5 corresponds to random guessing, and one corresponds to the error—free separation of groups. The model, which took into account the condition of the amygdala and the entorhinal region, received 0.665. With the same proportion of correctly identified violations, the second model was less likely to mistakenly classify people from the control group as participants with violations.

The absolute volume of the structures varied depending on the tomograph. Estimates of the rate of atrophy calculated from a series of images turned out to be comparable within each group on devices from different manufacturers.

To find out whether this approach is suitable for forecasting, it will be necessary to follow people with preserved cognitive functions and compare the initial images with those who developed impairments in subsequent years. Repeated measurements could also help in trials of new drugs, where it is important to understand whether the rate of atrophy changes during treatment.

In Russian practice, if Alzheimer's disease is suspected, CT or MRI scans help assess the nature of the atrophy and rule out other possible causes of symptoms, such as a brain tumor. When making a diagnosis, doctors compare the pictures with the medical history, examination data and the results of neuropsychological tests. This approach is provided for by the clinical recommendations of the Russian Ministry of Health.

The American Alzheimer's Association recommends testing people without symptoms for biomarkers of the disease as part of scientific research.

"As biomarkers and treatments become more accessible, it will be especially important to understand who may have cognitive impairment. This could help to accurately assess the risk and start treatment earlier to try to slow down the course of the disease," said Megan Morris, a neuropathologist at Johns Hopkins University School of Medicine.

Переведено сервисом «Яндекс Переводчик»

Live broadcast